°æ±¸ °íÇü Á¦Á¦ Á¦Á¶ ½ÃÀå : ¿Ï¼º Á¦Çüº°, Æ÷Àå Çüź°, »ç¾÷ ±Ô¸ðº°, ±â¾÷ ±Ô¸ðº°, Ä¡·á ¿µ¿ªº°, ÁÖ¿ä Áö¿ªº° - ¾÷°è µ¿Çâ°ú ¼¼°è ¿¹Ãø(- 2035³â)
Oral Solid Dosage Manufacturing Market by Type of Finished Dosage Form, Type of Packaging, Scale of Operation, Company Size, Therapeutic Area, and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035
»óǰÄÚµå : 1682705
¸®¼­Ä¡»ç : Roots Analysis
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 296 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,799 £Ü 6,943,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 10,126,000
PDF (One-Location Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ Æ¯Á¤ »ç¾÷ ºÎ¹®¿¡ ¼ÓÇÑ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,599 £Ü 15,335,000
PDF (Department License) help
PDF º¸°í¼­¸¦ ºÎ¼­ ´ÜÀ§·Î 12¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,999 £Ü 26,042,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è °æ±¸ °íÇü Á¦Á¦ Á¦Á¶ ½ÃÀå ±Ô¸ð´Â 2035³â±îÁö ¿¹Ãø ±â°£ µ¿¾È 4.49%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÇ¾î ÇöÀç 225¾ï ´Þ·¯¿¡¼­ 2035³â±îÁö 365¾ï 2,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀǾàǰ ¹× °Ç°­±â´É½Äǰ ºÐ¾ß¿¡¼­ ¿©·¯ °¡Áö »õ·Î¿î Á¦ÇüÀÌ µµÀԵǰí ÀÖÀ½¿¡µµ ºÒ±¸Çϰí, °æ±¸¿ë °íÇüÁ¦(OSD), ƯÈ÷ Á¤Á¦ ¹× ĸ½¶Àº ¿©ÀüÈ÷ °¡Àå Àαâ ÀÖ°í ³Î¸® »ç¿ëµÇ´Â Àü´Þ ÇüÅÂÀÔ´Ï´Ù. ÀÌ´Â ÀÌ·¯ÇÑ Á¦ÇüÀÌ ÀÚ°¡ Åõ¿©, ¾ÈÁ¤¼º, ºñ¿ë È¿À²¼º, Ãë±Þ ¹× ¿î¼Û ÆíÀǼº, ȯÀÚ ¼øÀÀµµ µî ´Ù¾çÇÑ ÀÌÁ¡À» Á¦°øÇϱ⠶§¹®ÀÔ´Ï´Ù. Á¦¾à »ê¾÷ Àüü¿¡¼­ ÀÌ ¼º¼÷ÇÏ°íµµ °íºÎ°¡°¡Ä¡ ºÐ¾ß´Â ÀÎü¿ë Á¦Á¦ ¼¼°è ½ÃÀå Á¡À¯À²ÀÇ ¾à 90%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

±×·¯³ª OSD Á¦Á¶ °øÁ¤Àº Ư¼ö Àåºñ¿Í ½Ã¼³, °íµµ·Î ÅëÁ¦µÈ ÀÛ¾÷ ȯ°æ, ´ÙÇÐÁ¦Àû Áö½ÄÀ» °®Ãá Àü¹®°¡¸¦ ÇÊ¿ä·Î ÇÏ´Â º¹ÀâÇÑ °úÁ¤ÀÔ´Ï´Ù. ¶ÇÇÑ, ³·Àº »ýü ÀÌ¿ë·ü, ³·Àº ¿ëÇØµµ, ¾´¸À, ³ôÀº ¿ª°¡ µî ¿ø·áÀǾàǰ°ú °ü·ÃµÈ ¾÷½ºÆ®¸² º´¸ñÇö»óÀ» ÇØ°áÇϱâ À§ÇÑ ÃÖ±ÙÀÇ ¹ßÀüÀº ±¤¹üÀ§ÇÑ ±â¼úÀû Àü¹®Áö½ÄÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ±× °á°ú, Á¦¾à»çµéÀº ºñ¿ë Àý°¨ ±âȸ¸¦ ¾ò±â À§ÇØ À§Å¹ ¼­ºñ½º Á¦°ø¾÷ü¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í ´Þ¸®, ÀÌ·¯ÇÑ Á¦3ÀÚ ¼­ºñ½º Á¦°ø¾÷üÀÇ ¿ª·®Àº ÀϹÝÀûÀ¸·Î °¢°¢ÀÇ ¼­ºñ½º Æ÷Æ®Æú¸®¿À¿¡ ÁýÁߵǾî ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº Á¦¹ý ¹× Á¦Á¦ °³¹ßºÎÅÍ ¿ø·áÀǾàǰ Ư¼º Æò°¡, ºÐ¼®¹ý °³¹ß, ±ÔÁ¦ ´ç±¹ ½Åû, ÀÓ»ó ¹× »ó¾÷ »ý»ê ´É·Â¿¡ À̸£±â±îÁö Àü¹®ÀûÀÎ ¿ª·®À¸·Î Á¦¾à»ç¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¾Æ¿ô¼Ò½ÌÀÇ È®´ë Ãß¼¼¿Í ¼­ºñ½º Á¦°ø¾÷üµéÀÌ Áö¼ÓÀûÀ¸·Î ¼­ºñ½º °³¼± ¹× È®´ë¿¡ Èû¾²°í ÀÖ´Â Á¡À» °í·ÁÇÒ ¶§, °æ±¸¿ë °íÇüÁ¦ À§Å¹»ý»ê ½ÃÀåÀº ÁßÀå±âÀûÀ¸·Î ²ÙÁØÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇöÀç 300°³ ÀÌ»óÀÇ ±â¾÷ÀÌ Á¤Á¦ ¹× ĸ½¶ ¼­¹æÇü Á¦Á¦¸¦ Æ÷ÇÔÇÑ ±¤¹üÀ§ÇÑ °æ±¸¿ë °íÇüÁ¦ ¼öŹ Á¦Á¶ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ ÇÊ¿äÇÑ Àü¹® Áö½ÄÀ» º¸À¯Çϰí ÀÖ´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù. ¾à 30%ÀÇ ±â¾÷ÀÌ Ãʱ⠰³¹ßºÎÅÍ ´Ù¾çÇÑ ¿ë±â¿¡ °æ±¸¿ë °íÇü Á¦Á¦ÀÇ Æ÷Àå¿¡ À̸£±â±îÁö ¿£µå Åõ ¿£µå ¿ª·®À» °®Ãß°í ÀÖ¾î ½ºÆù¼­ ±â¾÷°ø±Þ¾÷ü °ü¸® Ȱµ¿À» °£¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç ½ÃÀå »óȲÀº ±ÔÁ¦ »óȲ¿¡ µû¶ó ´Ù¾çÇÑ ±Ô¸ðÀÇ °æ±¸ °íÇü Á¦Á¦ Á¦Á¶¿¡ Á¾»çÇÏ´Â ±âÁ¸ ¹× ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷µéÀÌ Á¸ÀçÇϸç, 1,350°³ ÀÌ»óÀÇ ½Ã¼³À» °®Ãá °æ±¸¿ë °íÇüÁ¦ À§Å¹ »ý»ê ¾÷üµéÀÌ Àü ¼¼°èÀûÀ¸·Î Á¸Àç°¨À» µå·¯³»°í ÀÖ½À´Ï´Ù. ÀÌµé ¾÷ü ´ëºÎºÐÀº ÁÖ·Î Áß±¹, Àεµ µî ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡ ±â¹ÝÀ» µÎ°í ÀÖ½À´Ï´Ù.

Oral Solid Dosage Manufacturing Market-IMG1
Oral Solid Dosage Manufacturing Market-IMG2

¼¼°èÀÇ °æ±¸ °íÇü Á¦Á¦ Á¦Á¶ ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ¿ÏÁ¦ Çüź°/Æ÷Àå Çüź°/»ç¾÷ ±Ô¸ðº°/±â¾÷ ±Ô¸ðº°/Ä¡·á ¿µ¿ªº°/ÁÖ¿ä Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼­·Ð

Á¦4Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶Á¶Á÷(CMO) : ½ÃÀå ±¸µµ

Á¦5Àå ±â¾÷ °æÀï·Â ºÐ¼®

Á¦6Àå Áö¿ª ´É·Â ºÐ¼®

Á¦7Àå ±â¾÷ °³¿ä

Á¦8Àå Á¦Á¶ vs. ±¸ÀÔ ÀÇ»ç ÀÇ»ç°áÁ¤ ÇÁ·¹ÀÓ¿öÅ©

Á¦9Àå ÃÖ±Ù È®Àå

Á¦10Àå ¿ë·® ºÐ¼®

Á¦11Àå ¼ö¿ä ºÐ¼®

Á¦12Àå °æ±¸ °íÇü Á¦Á¦ ¼öŹÁ¦Á¶Á¶Á÷ÀÇ ÃÑ ¼ÒÀ¯ºñ¿ë

Á¦13Àå °æ±¸ °íÇü Á¦Á¦ °è¾à Á¦Á¶¾÷ü¿¡ ´ëÇÑ ±ÔÁ¦ »óȲ

Á¦14Àå ¹Ì°¢ ¸¶½ºÅ· ¼­ºñ½º¿Í ±â¼ú¿¡ °üÇÑ »ç·Ê ¿¬±¸ : ½ÃÀå ±¸µµ

Á¦15Àå »ýüÀÌ¿ë·ü Çâ»ó ±â¼ú¿¡ °üÇÑ »ç·Ê ¿¬±¸ : ½ÃÀå ±¸µµ

Á¦16Àå ½ÃÀå ¿¹Ãø

Á¦17Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦18Àå °á·Ð

Á¦19Àå ºÎ·Ï 1 : Ç¥ Çü½Ä µ¥ÀÌÅÍ

Á¦20Àå ºÎ·Ï 2 : ±â¾÷ ¹× ´Üü ¸®½ºÆ®

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global oral solid dosage contract manufacturing market is estimated to grow from USD 22.5 billion in the current year to USD 36.52 billion by 2035, at a CAGR of 4.49% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Finished Dosage Form

Type of Packaging

Scale of Operation

Company Size

Therapeutic Area

Key Geographical Regions

ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

Despite several novel dosage forms being introduced into the pharmaceutical and nutraceutical sectors, oral solid drugs (OSD), particularly tablets and capsules, continue to be the most popular and widely used delivery forms. This is due to the fact that these formulations offer various advantages, including self-administration, stability, cost-effectiveness, convenience of handling, transportation and patient compliance. This mature yet high-value vertical of the overall pharmaceutical industry represents about 90% of the global market share of all formulations intended for human use.

However, OSD manufacturing operations is a complex process requiring specialized equipment and facilities, highly contained working environments and experts with multidisciplinary knowledge. Further, recent evolution to address the upstream bottlenecks associated with active pharmaceutical ingredients (API), such as poor bioavailability, low solubility, bitter taste and high potency, necessitate extensive technical expertise. As a result, drug developers are increasingly relying on contract service providers to leverage their capabilities and yield cost savings opportunities. Unlike drug developers, the capabilities of these third-party service providers are usually more focused on their respective service portfolios. They support pharmaceutical companies with specialized capabilities ranging from process and formulation development to drug substance characterization, analytical method development, and regulatory filings, as well as capacity for clinical and commercial manufacturing. Considering the growing trend of outsourcing and the ongoing efforts of service providers to improve / expand their offerings, it is anticipated that the oral solid dosage contract manufacturing market is likely to evolve at a steady pace, in the mid to long term.

ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the oral solid dosage contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently, over 300 companies claim to have the required expertise to offer contract manufacturing services for a broad spectrum of oral solid dosage forms, including modified release formulations of tablets and capsules.

2. Nearly 30% of the players have established end-to-end capabilities, from early development to packaging of oral solids in a variety of containers; this simplifies supplier management activities for sponsor companies.

3. The current market landscape features the presence of both established and emerging players engaged in the manufacturing of oral solid dosages at various scales of operation, in compliance with the regulatory standards.

4. With more than 1,350 facilities, oral solid contract manufacturers have established global presence; majority of these players are based in the Asia-Pacific region, primarily in countries, such as China and India.

5. As part of their growth strategy, CMOs are investing in either expanding their existing facilities / capabilities or building facilities in other regions; majority of these initiatives were undertaken in North America.

Oral Solid Dosage Manufacturing Market - IMG1

6. The global installed oral solid dosage contract manufacturing capacity is spread across various geographies; over 30% of this capacity is dedicated to the manufacturing of tablets on a commercial scale.

7. The demand for oral solid dosage contract manufacturing is rising significantly owing to the growing complexity of APIs; by 2035, it is anticipated to reach over 35,000 metric tonnes, across clinical and commercial scales.

8. Driven by volume shifts from originators to generics and over-investments to create safety buffers, the contract manufacturing domain is currently witnessing an excess in capacity, thereby propelling consolidation efforts.

9. Over 65% of the market is expected to be captured by revenues from manufacturing anti-cancer drugs, including those based on HPAPIs; furthermore, North America based players are likely to contribute majorly to this domain.

Oral Solid Dosage Manufacturing Market - IMG2

ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

Tablets Occupy the Largest Share of the Oral Solid Dosage Contract Manufacturing Market

Based on the type of finished dosage form, the market is segmented into tablets, capsules, powders, multi-particulates and others. At present, tablets hold the maximum share of the oral solid dosage contract manufacturing market. This trend is likely to remain the same in the forthcoming years.

Blisters Segment is the Fastest Growing Segment of the Oral Solid Dosage Contract Manufacturing Market During the Forecast Period

Based on the type of packaging, the market is segmented into blisters, sachets, inhalers, bottles and others. Currently, bottles capture the highest proportion of the oral solid dosage contract manufacturing market. It is worth highlighting that the oral solid dosage contract manufacturing market for blisters is likely to grow at a relatively higher CAGR.

By Scale of Operation, Commercial Scale is Likely to Dominate the Oral Solid Dosage Contract Manufacturing Market

Based on the scales of operation, the market is segmented into pre-commercial and commercial scale. Whilst commercial scale manufacturing is expected to be the primary driver of the overall market, it is worth highlighting that the oral solid dosage contract manufacturing market at pre-commercial scale is likely to grow at a relatively higher CAGR.

Very Large Companies Occupy the Largest Share of the Oral Solid Dosage Contract Manufacturing Market

Based on the company size, the market is segmented into small, mid-sized, large and very large companies. At present, very large companies hold the maximum share of the oral solid dosage contract manufacturing market. This trend is unlikely to change in the foreseeable future.

Oncological Disorders Account for the Largest Share of the Oral Solid Dosage Contract Manufacturing Market

Based on the therapeutic areas, the market is segmented into oncological disorders, neurological disorders, cardiovascular disorders, infectious diseases, metabolic disorders, respiratory disorders, immunological disorders, genetic disorders, gastrointestinal disorders, other disorders. Currently, oncological disorders hold the maximum share of the oral solid dosage contract manufacturing market. This trend is likely to remain the same in the coming decade.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. The majority share is expected to be captured by players based in North America and Asia-Pacific.

Example Players in the Oral Solid Dosage Contract Manufacturing Market

ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. ORAL SOLID DOSAGE CONTRACT MANUFACTURING ORGANIZATIONS (CMOs): MARKET LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS

6. REGIONAL CAPABILITY ANALYSIS

7. COMPANY PROFILES

8. MAKE VERSUS BUY DECISION FRAMEWORK

9. RECENT EXPANSIONS

10. CAPACITY ANALYSIS

11. DEMAND ANALYSIS

12. TOTAL COST OF OWNERSHIP FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURING ORGANIZATIONS

13. REGULATORY LANDSCAPE FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURERS

14. CASE STUDY ON TASTE MASKING SERVICES AND TECHNOLOGIES: MARKET LANDSCAPE

15. CASE STUDY ON BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES: MARKET LANDSCAPE

16. MARKET FORECAST

17. EXECUTIVE INSIGHTS

18. CONCLUDING REMARKS

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â